IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

6/7/24 8:42:06 AM ET

Medical/Dental Instruments

Health Care

Get the next $IRMD alert in real time by email

IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol "IRMD." Stockholders are not required to take any action due to the uplisting.

Get the next $IRMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IRMD

Date	Price Target	Rating	Analyst
4/12/2023	$50.00	Buy	Lake Street

More analyst ratings

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "Being recognized by Fortune as one of the 100 Fastest Growing Companies for 2024 is a tremendous honor," said Roger Susi, President and Chief Executive Officer of the Company. "This achievement underscores our team's pas
11/4/24 8:30:00 AM ET
$IRMD
Medical/Dental Instruments
Health Care
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result
10/31/24 8:00:00 AM ET
$IRMD
Medical/Dental Instruments
Health Care
IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail
10/24/24 4:05:00 PM ET
$IRMD
Medical/Dental Instruments
Health Care

$IRMD
Financials

Live finance-specific insights

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result
10/31/24 8:00:00 AM ET
$IRMD
Medical/Dental Instruments
Health Care
IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail
10/24/24 4:05:00 PM ET
$IRMD
Medical/Dental Instruments
Health Care
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the third quarter of 2024, payable on August 30, 2024. WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Com
8/1/24 9:29:07 AM ET
$IRMD
Medical/Dental Instruments
Health Care

IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

Chat with this insight

Recent Analyst Ratings for
$IRMD

$IRMD
Market Insights

Live Market Insights

IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

IRADIMED Expects Q2 Adjusted EPS Of $1.52-$1.62 Versus Consensus Of $1.38

IRADIMED Expects Q2 Revenues Of $17.6M-$17.8M Versus Consensus Of $17.88M

$IRMD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$IRMD
Press Releases

Fastest customizable press release news feed in the world

$IRMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Lake Street initiated coverage on iRadimed with a new price target

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

$IRMD
SEC Filings

SEC Form 144 filed by iRadimed Corporation

SEC Form 10-Q filed by iRadimed Corporation

iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IRMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Vuoto Anthony sold $150,616 worth of shares (2,690 units at $55.99), decreasing direct ownership by 16% to 14,234 units (SEC Form 4)

Director Scharen-Guivel Hilda Frederique converted options into 1,767 shares, increasing direct ownership by 100% to 3,533 units (SEC Form 4)

Allen Monty K sold $84,432 worth of shares (1,947 units at $43.37), decreasing direct ownership by 10% to 18,053 units (SEC Form 4)

$IRMD
Financials

Live finance-specific insights

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

$IRMD
Leadership Updates

Live Leadership Updates

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

Chat with this insight

Recent Analyst Ratings for $IRMD

$IRMD Market Insights

Live Market Insights

IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

IRADIMED Expects Q2 Adjusted EPS Of $1.52-$1.62 Versus Consensus Of $1.38

IRADIMED Expects Q2 Revenues Of $17.6M-$17.8M Versus Consensus Of $17.88M

$IRMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$IRMD Press Releases

Fastest customizable press release news feed in the world

$IRMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Lake Street initiated coverage on iRadimed with a new price target

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

$IRMD SEC Filings

SEC Form 144 filed by iRadimed Corporation

SEC Form 10-Q filed by iRadimed Corporation

iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IRMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Vuoto Anthony sold $150,616 worth of shares (2,690 units at $55.99), decreasing direct ownership by 16% to 14,234 units (SEC Form 4)

Director Scharen-Guivel Hilda Frederique converted options into 1,767 shares, increasing direct ownership by 100% to 3,533 units (SEC Form 4)

Allen Monty K sold $84,432 worth of shares (1,947 units at $43.37), decreasing direct ownership by 10% to 18,053 units (SEC Form 4)

$IRMD Financials

Live finance-specific insights

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

$IRMD Leadership Updates

Live Leadership Updates

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

Recent Analyst Ratings for
$IRMD

$IRMD
Market Insights

$IRMD
Analyst Ratings

$IRMD
Press Releases

$IRMD
Large Ownership Changes

$IRMD
SEC Filings

$IRMD
Insider Trading

$IRMD
Financials

$IRMD
Leadership Updates